Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial

Hepatology

Volumn 21, Issue 2, 1995, Pages 291-297

  Kasahara, Akinori ^a   Hayashi, Norio ^a   Hiramatsu, Naoki ^a   Oshita, Masahide ^a   Hagiwara, Hideki ^a   Katayama, Kazuhiro ^a   Kato, Michio ^b   Masuzawa, Manabu ^b   Yoshihara, Harumasa ^c   Kishida, Yutaka ^d   Shimizu, Yoji ^e   Inoue, Atsuo ^f   Fusamoto, Hideyuki ^a   Kamada, Takenobu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Osaka Minami National Hospital   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

^d OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^e OSAKA GENERAL MEDICAL CENTER   (Japan)

^f CENTER FOR ADULT DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; FEMALE; HEPATITIS A; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADULT; ALANINE TRANSAMINASE; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS;

EID: 0028937539     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/0270-9139(95)90083-7     Document Type: Article

References (37)

1. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
2. Treatment of chronic non-A, nonB hepatitis with recombinant human alpha interferon
3. The hepatitis interventional therapy group. Treatment of chronic hepatitis C with recombinant interferon alpha
4. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind placebo-controlled trial
5. High doses of recombinant a-interferon or y-interferon for chronic hepatitis C: A randomized, controlled trial
6. Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France
7. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
8. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-a
9. Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha
10. Histologic changes in liver biopsy specimens produced by recombinant interferon a-2b therapy for chronic non-A, non-B viral hepatitis
11. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis
12. Interferon a-2b therapy reduces liver fibrosis in chronic non-A; non-B hepatitis: a quantitative histological evaluation
13. Detection of hepatitis C virus RNA in chronic non-A, non-B liver disease
14. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
15. Detection of hepatitis C viral sequence in non-A, non-B hepatitis
16. Detection, semiquantitation and genetic variation in hepatitis C virus sequence amplified from the plasma of blood donors with elevated alanine aminotransferase
17. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction
18. Detection of minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue
19. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon
20. Le Groupe Français Pour L'etude du Traitement des Hepatites Chroniques NANB/C
21. Structure and organization of the hepatitis C virus genome isolated from human carriers
22. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A; non-B hepatitis
23. Genetic organization and diversity of the hepatitis C virus
24. There are major types of hepatitis C virus in Japan
25. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes
26. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources
27. A proposed system for the nomenclature of hepatitis C viral genotypes
28. Clinical backgrounds of the patients having different types of hepatitis C virus genomes
29. Detection of hepatitis C virus by polymerase chain reaction and response to interferon therapy: relationship to genotypes of hepatitis C virus
30. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer
31. Factors predictive of response to interferon-α therapy in hepatitis C virus infection
32. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease
33. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
34. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
35. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection
36. Transforming growth factors β1 and a in chronic liver disease